Literature DB >> 24702855

Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.

Nobuhiro Asai1, Etsuro Yamaguchi2, Akihito Kubo2.   

Abstract

Entities:  

Keywords:  Crizotinib; EML4-ALK; Interstitial lung disease; Lung cancer

Mesh：

Substances：

Year:  2013        PMID： 24702855     DOI： 10.1016/j.cllc.2013.12.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

Review 1.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

2.  Successful crizotinib rechallenge after crizotinib-induced organizing pneumonia in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Nobuhiro Asai; Toyoharu Yokoi; Etsuro Yamaguchi; Akihito Kubo
Journal:  Case Rep Oncol       Date:  2014-09-27

3.  Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors.

Authors:  Hye Jeon Hwang; Mi Young Kim; Chang-Min Choi; Jae Cheol Lee
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.